Skip to main content
Premium Trial:

Request an Annual Quote

Incyte Expands, Extends Johnson & Johnson Deal

Premium

PALO ALTO, Calif.--Incyte Pharmaceuticals this month expanded a genomic partnership with Johnson & Johnson that began in 1996. Johnson & Johnson will receive access to multiple Incyte databses in exchange for annual fees, future milestone payments, and royalties to Incyte on the sale of products developed with its technology and data.

Among the databases is Incyte's newest product, the LifeSeq Gold assembled database, an extensive source of human gene and expression information assembled from preexisting Incyte databases using new and proprietary bioinformatics algorithms. Incyte claimed LifeSeq Gold is the most complete set of genetic data available on the human genome.

The deal also gives Johnson & Johnson access to Incyte's LifeSeq Atlas mapping and ZooSeq animal gene sequence and expression databases, as well as continued access to the PathoSeq microbial database.

Filed under

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.